TBEV preM
Description
Product Specs
Product Science Overview
Tick-borne encephalitis virus (TBEV) is a significant human pathogen belonging to the family Flaviviridae. It is primarily transmitted by ticks and is responsible for causing tick-borne encephalitis (TBE), a severe disease affecting the central nervous system. TBEV is prevalent in Europe and Asia, with up to 15,000 clinical cases reported annually .
The pre-membrane (prM) and envelope (E) proteins of TBEV play crucial roles in the virus’s life cycle and its ability to infect host cells. The prM protein is a precursor to the membrane (M) protein, which, along with the E protein, forms the viral envelope. The E protein is responsible for virus attachment and entry into host cells.
Recombinant TBEV preM involves the expression of the prM and E proteins in a host system, such as mammalian cells, using recombinant DNA technology. This approach allows for the production of subviral particles that mimic the native virus’s structure and antigenic properties. These recombinant subviral particles are valuable for diagnostic purposes and vaccine development .
Recombinant TBEV preM subviral particles have shown promise in diagnostic applications. They can be used to develop enzyme immunoassays (EIAs) for detecting TBEV-specific antibodies in human serum samples. These assays have demonstrated high sensitivity and specificity, making them reliable tools for TBEV serology .
The recombinant Modified Vaccinia virus Ankara (MVA) expressing the prM and E proteins of TBEV (MVA-prME) has been developed as a potential next-generation vaccine. Studies have shown that MVA-prME is highly immunogenic and provides full protection against TBEV infection in animal models. This recombinant vaccine holds promise for improving TBE prevention .
